Literature DB >> 2901605

Serological differences between verocytotoxin 2 and shiga-like toxin II.

S C Head, M A Karmali, M E Roscoe, M Petric, N A Strockbine, I K Wachsmuth.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 2901605     DOI： 10.1016/s0140-6736(88)90228-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  18 in total

1.  Glycolipid modification of alpha 2 interferon binding. Sequence similarity between the alpha 2 interferon receptor and verotoxin (Shiga-like toxin) B-subunit.

Authors:  C A Lingwood; S K Yiu
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

2.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

3.  Identification and characterization of a newly isolated shiga toxin 2-converting phage from shiga toxin-producing Escherichia coli.

Authors:  M Watarai; T Sato; M Kobayashi; T Shimizu; S Yamasaki; T Tobe; C Sasakawa; Y Takeda
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

4.  Identification of verotoxin type 2 variant B subunit genes in Escherichia coli by the polymerase chain reaction and restriction fragment length polymorphism analysis.

Authors:  S D Tyler; W M Johnson; H Lior; G Wang; K R Rozee
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

5.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.

Authors:  M Bitzan; M Klemt; R Steffens; D E Müller-Wiefel
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

6.  Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro.

Authors:  M Bitzan; S Richardson; C Huang; B Boyd; M Petric; M A Karmali
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide.

Authors:  Steven D Zumbrun; Leanne Hanson; James F Sinclair; James Freedy; Angela R Melton-Celsa; Jaime Rodriguez-Canales; Jeffrey C Hanson; Alison D O'Brien
Journal:  Infect Immun       Date:  2010-08-23       Impact factor: 3.441

8.  Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits.

Authors:  D J Bast; J L Brunton; M A Karmali; S E Richardson
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

9.  Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli.

Authors:  M A Karmali; M Petric; M Bielaszewska
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

10.  Development of verotoxin 2- and verotoxin 2 variant (VT2v)-specific oligonucleotide probes on the basis of the nucleotide sequence of the B cistron of VT2v from Escherichia coli E32511 and B2F1.

Authors:  J H Hii; C Gyles; T Morooka; M A Karmali; R Clarke; S De Grandis; J L Brunton
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.